Skip to main content

Table 4 Effect of different factors on statin expenditure changes*

From: Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea

  2005 2006 2007 2008 2009 Average
Year-on-year increased statin expenditure rate (%)* (T)   35.92 26.90 11.60 14.99 21.97
Core medicines (year-to-year rates of increase: %, A)   46.62 23.61 2.32 14.17 18.24
  - Price (P)   −7.18 −0.33 −0.22 −6.21 −2.98
  -Within-component mix (generic mix)   5.36 −2.12 −1.77 −2.06 −0.90
  -Between-component mix   4.54 0.83 0.10 1.19 1.36
      (Ingredient mix)
  - Volume (Q)   47.94 32.21 5.04 21.58 23.48
New entrants (year-to-year rates of increase: %, B)   2.69 3.30 10.54 0.96 6.43
  - New molecular entities   0.00 0.00 0.00 0.00 0.00
  - New medicines   0.00 0.00 0.01 0.34 0.12
  - New generic medicines   1.87 3.23 10.53 0.30 5.13
  - Others   0.82 0.07 0.00 0.32 0.26
Exiting medicines (year-to-year rates of increase: %, C)   −13.39 0.00 −1.26 −0.14 −2.70
  1. *The drug expenditure was adjusted for inflation.